Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.46 |
| ▸ | HTR2A | P28223 | 3/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 11/20 | 0.40 |
| ▸ | DRD2 | P14416 | 10/20 | 0.40 |
| ▸ | HTR1A | P08908 | 6/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | HHAT | Q5VTY9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1095555 | 0.84 | ESR1 (0.49) | ESR1ESR2HTR2AHTR2CHTR2B | |
| SCHEMBL3282297 | 0.84 | ESR1 (0.49) | ESR1ESR2HTR2AHTR2CHTR2B | |
| SCHEMBL3282323 | 0.84 | ESR1 (0.49) | ESR1ESR2HTR2AHTR2CHTR2B | |
| SCHEMBL31121204 | 0.84 | ESR1 (0.49) | ESR1ESR2HTR2AHTR2CHTR2B | |
| SCHEMBL1094747 | 0.80 | MTNR1B (0.43) | ESR1ESR2HTR2AHTR2CHTR2B | |
| SCHEMBL2200990 | 0.79 | HTR2A (0.56) | HTR2AHTR2CHTR2BDRD3DRD2 | |
| SCHEMBL1095554 | 0.77 | ESR1 (0.61) | ESR1ESR2 | |
| SCHEMBL1096119 | 0.76 | HTR2C (0.50) | ESR1ESR2HTR2AHTR2CHTR2B | |
| SCHEMBL2585109 | 0.76 | ESR1 (0.62) | ESR1ESR2HTR2AHTR2CHTR2B | |
| SCHEMBL25206226 | 0.73 | ESR2 (0.76) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2374796-B1 | 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorderes | ARENA PHARM INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160250223-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2016-09-01 | — | — | US | disclosed |
| US-20160024014-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2016-01-28 | — | — | US | disclosed |
| US-8993750-B2 | 5HT2C receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20150087634-A1 | 5HT2C RECEPTOR MODULATOR COMPOSITIONS | ARENA PHARMACEUTICALS, INC. | 2015-03-26 | — | — | US | disclosed |
| US-20150045552-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2015-02-12 | — | — | US | disclosed |
| US-8846906-B2 | 5HT2C receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8575149-B2 | 5HT2C receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8546379-B2 | 5HT2C receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546378-B2 | 5HT2C receptor modulator compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20070060568-A1 | Obesity therapy; using 3-benzoazepine compound | ARENA PHARMACEUTICALS, A DELAWARE CORPORATION | 2007-03-15 | — | — | US | disclosed |
| EP-1411881-B9 | 5HT2C RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2006-11-15 | — | — | EP | disclosed |
| US-6953787-B2 | 5HT2C receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2005-10-11 | — | — | US | disclosed |
| EP-1557409-A1 | 5HT2C receptor modulators | Arena Pharmaceuticals, Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-1411881-B1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2005-05-04 | — | — | EP | disclosed |
| US-20050020573-A1 | Obesity; using 3-benoazepine compound | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | US | disclosed |
| EP-1411881-A4 | 5HT sb 2C /sb RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2004-07-07 | — | — | EP | disclosed |
| EP-1411881-A2 | 5HT sb 2C /sb RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030225057-A1 | 3-Benzoazepine derivatives | ARENA PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | US | disclosed |
| WO-2003086306-A2 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225057-A1 | 3-Benzoazepine derivatives | HTR2C, HTR1A, HTR3A | ESR1 1510/4885ESR2 848/4885HTR2A 13/4885 |
| US-20050020573-A1 | Obesity; using 3-benoazepine compound | HTR2C, HTR3C, HTR3B | ESR1 2872/4885ESR2 1307/4885HTR2A 7/4885 |
| US-20070060568-A1 | Obesity therapy; using 3-benzoazepine compound | HTR2C, HTR3B, HTR3C | ESR1 1112/4885ESR2 733/4885HTR2A 8/4885 |
| US-20150087634-A1 | 5HT2C RECEPTOR MODULATOR COMPOSITIONS | HTR2C, HTR2A, HTR5A | ESR1 1578/4885ESR2 1476/4885HTR2A 2/4885 |
| US-20160024014-A1 | 5HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | ESR1 1469/4885ESR2 559/4885HTR2A 2/4885 |
| US-20150045552-A1 | 5HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | ESR1 1469/4885ESR2 559/4885HTR2A 2/4885 |
| US-20160250223-A1 | 5HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | ESR1 1469/4885ESR2 559/4885HTR2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.